Prevention of induced nausea and vomiting in patients with malignant blood disorders. Experience of using netupitant/palonosetron (Akynzeo)

Abstract

Supporting therapy is a necessary component of successful antitumor treatment in patients with both solid tumors and malignant blood disorders. Adherence to administration protocol for antiemetic drugs aimed at prevention of induced gastrointestinal complications (nausea and vomiting), allows to improve patients' quality of life and treatment compliance. Development of a combination antiemetic drug (netupitant/palonosetron) simultaneously affecting 2 main mechanisms of nausea and vomiting as well as its easy administration allowed to significantly improve control of these complications in patients with solid tumors and patients with malignant blood disorders.We present a literature review on the effectiveness of netupitant/palonosetron and describe our own experience of using this antiemetic drug for prevention of chemotherapy-induced nausea and vomiting.